You have accessed https://www.emdserono.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.
You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser
You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.
If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website.
By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.
Cookie Disclaimer
This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re Ok with this. You can change which cookies are set at any time - and find out more about our cookie policy.
Our targeted therapy has been FDA approved for the treatment of certain patients with a form of metastatic non-small cell lung cancer.
Read the Press ReleaseEMD Serono’s Embracing Carers™ initiative announces study results of COVID-19 on caregivers
Embracing CarersWe are taking actions to minimize the spread of the virus while ensuring that our medicines and services continue to reach those who rely on them.
Our Response